rs191758096

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2

The NM_000069.3(CACNA1S):​c.3795+3G>A variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00167 in 1,614,124 control chromosomes in the GnomAD database, including 15 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0013 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0017 ( 14 hom. )

Consequence

CACNA1S
NM_000069.3 splice_region, intron

Scores

2
Splicing: ADA: 0.0003253
2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:15

Conservation

PhyloP100: 0.645

Publications

0 publications found
Variant links:
Genes affected
CACNA1S (HGNC:1397): (calcium voltage-gated channel subunit alpha1 S) This gene encodes one of the five subunits of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Mutations in this gene have been associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis and malignant hyperthermia susceptibility. [provided by RefSeq, Jul 2008]
CACNA1S Gene-Disease associations (from GenCC):
  • congenital myopathy 18
    Inheritance: AD, AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • hypokalemic periodic paralysis, type 1
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
  • malignant hyperthermia, susceptibility to, 5
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • congenital myopathy
    Inheritance: SD, AR, AD Classification: STRONG Submitted by: Illumina, Genomics England PanelApp
  • hypokalemic periodic paralysis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.48).
BP6
Variant 1-201053456-C-T is Benign according to our data. Variant chr1-201053456-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 254827.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.00128 (195/152248) while in subpopulation SAS AF = 0.00538 (26/4830). AF 95% confidence interval is 0.00377. There are 1 homozygotes in GnomAd4. There are 100 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAdExome4 at 14 AD,AR,SD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNA1SNM_000069.3 linkc.3795+3G>A splice_region_variant, intron_variant Intron 30 of 43 ENST00000362061.4 NP_000060.2
CACNA1SXM_005245478.4 linkc.3738+3G>A splice_region_variant, intron_variant Intron 29 of 42 XP_005245535.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNA1SENST00000362061.4 linkc.3795+3G>A splice_region_variant, intron_variant Intron 30 of 43 1 NM_000069.3 ENSP00000355192.3

Frequencies

GnomAD3 genomes
AF:
0.00128
AC:
195
AN:
152130
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000290
Gnomad AMI
AF:
0.00987
Gnomad AMR
AF:
0.000982
Gnomad ASJ
AF:
0.00865
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00538
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.00146
Gnomad OTH
AF:
0.000957
GnomAD2 exomes
AF:
0.00198
AC:
497
AN:
251402
AF XY:
0.00225
show subpopulations
Gnomad AFR exome
AF:
0.000431
Gnomad AMR exome
AF:
0.00142
Gnomad ASJ exome
AF:
0.00764
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000231
Gnomad NFE exome
AF:
0.00164
Gnomad OTH exome
AF:
0.00424
GnomAD4 exome
AF:
0.00171
AC:
2494
AN:
1461876
Hom.:
14
Cov.:
35
AF XY:
0.00187
AC XY:
1362
AN XY:
727242
show subpopulations
African (AFR)
AF:
0.000179
AC:
6
AN:
33480
American (AMR)
AF:
0.00145
AC:
65
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00865
AC:
226
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39700
South Asian (SAS)
AF:
0.00486
AC:
419
AN:
86258
European-Finnish (FIN)
AF:
0.000225
AC:
12
AN:
53410
Middle Eastern (MID)
AF:
0.00399
AC:
23
AN:
5768
European-Non Finnish (NFE)
AF:
0.00144
AC:
1596
AN:
1112004
Other (OTH)
AF:
0.00243
AC:
147
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.471
Heterozygous variant carriers
0
155
311
466
622
777
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
68
136
204
272
340
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00128
AC:
195
AN:
152248
Hom.:
1
Cov.:
32
AF XY:
0.00134
AC XY:
100
AN XY:
74438
show subpopulations
African (AFR)
AF:
0.000289
AC:
12
AN:
41538
American (AMR)
AF:
0.000980
AC:
15
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.00865
AC:
30
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5162
South Asian (SAS)
AF:
0.00538
AC:
26
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10622
Middle Eastern (MID)
AF:
0.00340
AC:
1
AN:
294
European-Non Finnish (NFE)
AF:
0.00147
AC:
100
AN:
68008
Other (OTH)
AF:
0.000947
AC:
2
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
11
22
32
43
54
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00167
Hom.:
0
Bravo
AF:
0.00141
Asia WGS
AF:
0.00202
AC:
7
AN:
3478
EpiCase
AF:
0.00267
EpiControl
AF:
0.00302

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:15
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:5
Apr 15, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 26, 2017
Institute for Genomic Medicine (IGM) Clinical Laboratory, Nationwide Children's Hospital
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

BS1,BP6; This alteration has an allele frequency that is greater than expected for the associated disease, and was reported as a benign/likely benign alteration by a reputable source (ClinVar or other correspondence from a clinical testing laboratory). -

Dec 02, 2019
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 07, 2020
Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypokalemic periodic paralysis, type 1 Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Apr 11, 2023
Genome-Nilou Lab
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Feb 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CACNA1S: BP4, BS2 -

Malignant hyperthermia, susceptibility to, 5 Benign:2
Sep 20, 2022
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 11, 2023
Genome-Nilou Lab
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypokalemic periodic paralysis Benign:1
Apr 05, 2024
Molecular Genetics Laboratory, BC Children's and BC Women's Hospitals
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Congenital myopathy 18 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Thyrotoxic periodic paralysis, susceptibility to, 1 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Malignant hyperthermia, susceptibility to, 5;C3714580:Hypokalemic periodic paralysis, type 1 Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.48
CADD
Benign
15
DANN
Benign
0.88
PhyloP100
0.65
Mutation Taster
=22/78
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.00033
dbscSNV1_RF
Benign
0.050
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs191758096; hg19: chr1-201022584; API